Nanite Inc. is thrilled to announce an exciting investment from the Cystic Fibrosis Foundation – a whopping $2 million! This funding will be used to develop gene delivery technologies for the treatment of the lung, and comes on the heels of the company’s $6M seed financing round. This major investment marks a huge milestone for Nanite Inc. and will undoubtedly lead to innovative, life-changing solutions.
Polymer nanoparticles (PNPs) are emerging as a cutting-edge delivery modality for the development of new therapies for cystic fibrosis patients, offering a range of advantages over other forms of genetic therapy delivery. Unlike viruses and lipid nanoparticles, PNPs are less likely to trigger an immune response, and can accommodate larger drug payloads than their lipid counterparts. Moreover, PNPs are highly stable and versatile, making them ideal for targeted drug delivery.
Nanite’s revolutionary SAYER™ platform is set to revolutionize the delivery of genetic material therapies to diverse tissues, combining high-throughput synthesis with artificial intelligence (AI). With its latest funding from the Foundation, Nanite is initially focusing on developing polymer nanoparticles that can accurately deliver mRNA therapies to the lung, while also aiming to tackle the sticky mucus that obstructs the airways of CF patients. In the future, Nanite hopes to expand its capabilities to deliver gene therapies to other organs affected by CF, such as the pancreas.
We are delighted to announce that the Cystic Fibrosis Foundation has made a substantial investment in our company, Nanite, to explore a new way of delivering genetic therapies directly to the lungs of CF patients. Our SAYER platform is an innovative combination of automated polymer synthesis, high-throughput in vivo screening, and AI, which enables us to design programmable polymer nanoparticles that can deliver a wide range of genetic cargoes with tissue specificity. We look forward to collaborating with other patient advocacy groups and biotech partners to develop advanced drug delivery systems for various indications.
About Nanite Inc.
Nanite is revolutionizing the way we deliver genetic cargoes with tissue specificity. By combining AI-driven technology with cutting-edge high-throughput experimental and computational methods, the Boston-based company has developed a new class of programmable polymer nanoparticles for a range of modalities and indications. With their innovative platform, SAYER™, Nanite is paving the way for a new era in non-viral gene delivery.